OKYO Pharma Ltd (OKYO) Form 6-K — Jul 23, 2026
OKYO Pharma CEO Robert J. Dempsey purchased 15,000 ordinary shares on NASDAQ at $1.54 per share, increasing his personal stake in the clinical-stage biopharmaceutical company. The buy, worth approximately $23,100, signals executive confidence as the firm prepares to initiate a global Phase 3 pivotal trial for its NCP treatment urcosimod in the second half of the year. The company is developing therapies for neuropathic corneal pain and anterior segment eye diseases, with its upcoming Phase 3 trial set to enroll approximately 111 patients.
Key figures
- Purchase Price
- 1.54
- Shares Purchased
- 15000
- Purchaser
- Robert J. Dempsey (CEO)
- Transaction date
- 2026-07-23
- Planned phase 3 patients
- 111
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.